Area of research
Pulmonary and Respiratory Medicine · Molecular Biology
Research interest
Research interests include PI3K/AKT/mTOR signaling in cancer, Chronic Lymphocytic Leukemia Research, Advanced Breast Cancer Therapies, and Lung Cancer Treatments and Mutations.
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed <i>NPM1-</i>m or <i>KMT2A</i>-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007
Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory <i>NPM1</i>-m or <i>KMT2A</i>-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007
Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in <i>PIK3CA</i> - and <i>HRAS</i> -Dysregulated HNSCC via Convergent Inhibition of mTOR Activity
Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia